

Errata to the FDA Briefing Document  
Oncologic Drugs Advisory Committee Meeting  
July 14, 2011  
Brentuximab vedotin (Adcetris™)  
Applicant: Seattle Genetics

BLA 125399 Errata #2

1. On Page 9 under Statistical Analysis Plan the sentence "SG035-0003 was designed to enroll approximately 55 subjects" should be replaced with "SG035-0004 was designed to enroll approximately 55 subjects."
2. On Page 12 under Disease Characteristics the sentence "Seventy-one percent were reported as having primary refractory disease" should read "Sixty-two percent were reported as having primary refractory disease."
3. Table 9 on page 17

**Table 9 Safety Overview of Study SG035-0004: ALCL**

<b>Event</b>	<b>N (%) Brentuximab Vedotin Patients</b>
Death Due to Adverse Event	0
Discontinuation Due to Adverse Event	11 (19)
Serious Adverse Events	9 (16)
Grade 3-4 Adverse Events	56 (55)

Should be replaced as follows:

**Table 9 Safety Overview of Study SG035-0004: ALCL**

<b>Event</b>	<b>N (%) Brentuximab Vedotin Patients</b>
Death Due to Adverse Event	0
Discontinuation Due to Adverse Event	11 (19)
Serious Adverse Events	23 (40)
Grade 3-4 Adverse Events	36 (62)